236 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (223)
- Addiction (6)
- Autoimmune Disorders (15)
- Blood Disorders (23)
- Bone & Muscle (1)
- Cancer (3)
- Child Development (1)
- Endocrine & Metabolic Disease (2)
- Hair and Skin Disorders (2)
- Healthy Volunteers (8)
- Heart Disease (1)
- Liver Disease (1)
- Lung Disease (1)
- Meniere's Disease (1)
- Neurological Disorders (102)
- Obstetrics & Gynecology (3)
- Pediatrics (5)
- Psychiatric Disorders (48)
Displaying 1 - 6 of 6
Condition: Psychiatric Disorders / Schizophrenia
Investigator: Joshua Kantrowitz, Md
Status: Closed
The purpose of this study is to evaluate the efficacy, safety and tolerability of different doses and durations of TV-46000 given by subcutaneous (under the skin) injection as compared to placebo for use as a potential maintenance in adults with schizophrenia.
Condition: Neurological Disorders / Dementia
Investigator: Justin Golub, MD, MS
Status: Currently Recruiting
Early Age-Related Hearing Loss Investigation (EARHLI) is a study to obtain information on how a hearing aid-based intervention can prevent cognitive decline in those at risk for Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). Age-related hearing loss (ARHL) is the third most common chronic condition in older adults. The…
Condition: Psychiatric Disorders / Schizophrenia
Investigator: Jeffrey Lieberman, MD
Status: Closed
This study plans to learn more about an investigational new drug called lumateperone tosylate (ITI-007) and may help us find new types of treatment for schizophrenia and schizoaffective disorder.
Condition: Neurological Disorders / Dementia
Investigator: Lawrence Honig, MD, PhD
Status: Closed
This is a 22-week treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 2 study to evaluate the efficacy, safety, and tolerability of the study drug E2027, in participants with Dementia with Lewy Bodies (DLB) Lewy Body Dementia - LBD. The main purpose of this research study is to find if a new drug called E2027 works in people who…
Condition: Neurological Disorders / Dementia
Investigator: Lawrence Honig, MD, PhD
Status: Closed
This study is of a drug called CT1812, that is being evaluated as a possible treatment for Dementia with Lewy Bodies. In this study, which is carried out at multiple sites in the country, participants receive either CT1812 at one of two doses or placebo. The duration of the study is up to about 35 weeks. Participants receive blood tests, cerebrospinal fluid…
Condition: Neurological Disorders / Dementia
Investigator: Sairam Geethanath, PhD
Status: Closed
A significant focus of healthcare research is aimed at biomarker discoveries in brain and heart diseases in particular, and their impact on the human body in general. MRI is a key component in these healthcare services. It provides a non-invasive and non-ionizing approach to diagnose pathologies along with significant internal and external contrast…